中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
IR
Sustainability
Join Us

News

Simcere Zaiming will present 7 innovative researches at the 2025 AACR

2025-04-15
Simcere Zaiming’s FGFR2b targeting ADC SIM0686 obtained IND approval from China NMPA

On April 10, 2025, Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that its independen...

2025-04-10
NDA of Deunoxavir Marboxil ,the Next Generation Innovative Influenza Drug get Accepted , Offering Hope for "One-Pill Cure" for Influenza.

Recently, the Phase III clinical study for pediatric indication of Deunoxavir Marboxil granules, an innovative anti-influenza drug jointly developed b...

2025-03-18
All Patients Enrolled in Phase III Clinical Study of Deunoxavir Marboxil for Pediatric Indication

Recently, the Phase III clinical study for pediatric indication of Deunoxavir Marboxil granules, an innovative anti-influenza drug jointly developed b...

2025-02-19
read more

6,500+

Staff

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

Partnering

Therapeutic Areas

Telephone: 025-85566666

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.